NCT06520345

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2024-07-26Est. Completion: 2027-12

Enrollment target: 520 participants

Locations

Chao Family Comprehensive Cancer Centre, Orange, California, United States
Biogenix Molecular LLC, Miami, Florida, United States
United Theranostics, Glen Burnie, Maryland, United States
XCancer Omaha, Omaha, Nebraska, United States
Columbia University Herbert Irving Comphrensive Cancer Center, New York, New York, United States
University Hospital, Cleveland, Ohio, United States
OHSU Knight Cancer Center, Portland, Oregon, United States
Intermountain Health, Murray, Utah, United States
Intermountain Health, Salt Lake City, Utah, United States
Westmead Hospital, Sydney, New South Wales, Australia
Nepean Hospital, Sydney, New South Wales, Australia
Wollongong Hospital, Wollongong, New South Wales, Australia
Australian Prostate Centre, Melbourne, Victoria, Australia
GenesisCare Murdoch, Perth, Western Australia, Australia
Mater Health Services Pty Ltd, Brisbane, Australia
GenesisCare Maitland, East Maitland, Australia
Austin Health, Heidelberg, Australia

Metastatic Castration-resistant Prostate Cancer

The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abira…

Goodyear, United StatesEst. completion Jan 7, 2030

Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer

Phase I: Characterize safety and tolerability of GVV858 as a single agent and in combination with fulvestrant or letrozo…

Nashville, United StatesEst. completion May 9, 2031

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.